Stock Events

Stock Events

Alterity Therapeutics 

$0
25
+$0+450% Wednesday 15:50

Statistics

Day High
0
Day Low
0
52W High
0.01
52W Low
0
Volume
10,000
Avg. Volume
9,543
Mkt Cap
11.96M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

25FebExpected
Q2 2023
Q3 2023
Q4 2023
Q2 2024
Q4 2024
Q2 2025
Q4 2025
-0
-0
-0
-0
Expected EPS
-0.0005389060173610135
Actual EPS
-0.000843505070652021

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-15.7MNet Income

Analyst Ratings

$0.00Average Price Target
The highest estimate is 0.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PRNAF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap22.63B
Biogen focuses on neurodegenerative diseases, directly competing with Alterity's focus on Parkinson's and Alzheimer's.
Palatin Technologies
PTN
Mkt Cap2.45M
Palatin Technologies works on novel therapeutics for diseases with a significant unmet medical need, including neurological disorders.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.83B
Acadia Pharmaceuticals specializes in central nervous system disorders, making it a direct competitor in the neurodegenerative disease space.
AnaptysBio
ANAB
Mkt Cap1.02B
AnaptysBio is involved in developing therapeutic antibodies, potentially competing in the neurodegenerative disease treatment market.
Anavex Life Sciences
AVXL
Mkt Cap684.57M
Anavex Life Sciences Corp. focuses on developing drugs for Alzheimer's disease and other central nervous system diseases.
Axsome Therapeutics
AXSM
Mkt Cap6.74B
Axsome Therapeutics develops therapies for central nervous system disorders, including Alzheimer's, directly competing with Alterity.
Ionis Pharmaceuticals
IONS
Mkt Cap12.03B
Ionis Pharmaceuticals develops RNA-targeted therapeutics, including for neurological disorders, competing in the same space as Alterity.
Prothena
PRTA
Mkt Cap578.67M
Prothena Corporation is focused on the discovery and development of novel antibodies for neurodegenerative diseases.
Voyager Therapeutics
VYGR
Mkt Cap259.04M
Voyager Therapeutics focuses on severe neurological diseases through gene therapy, competing in the broader neurodegenerative treatment market.

About

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
Show more...
CEO
Mr. Geoffrey Paul Kempler B.Sc.
Employees
10
Country
AU
ISIN
AU0000043945

Listings

AU
AU
ATH.AU
F
DE
PBN0.F
XNAS
US
ATHE
F
DE
PBN.F

0 Comments

Share your thoughts

FAQ

What is Alterity Therapeutics stock price today?▼
The current price of PRNAF is $0 USD — it has increased by +450% in the past 24 hours. Watch Alterity Therapeutics stock price performance more closely on the chart.
What is Alterity Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Alterity Therapeutics stocks are traded under the ticker PRNAF.
What is Alterity Therapeutics market cap?▼
Today Alterity Therapeutics has the market capitalization of 11.96M
When is the next Alterity Therapeutics earnings date?▼
Alterity Therapeutics is going to release the next earnings report on August 28, 2026.
What were Alterity Therapeutics earnings last quarter?▼
PRNAF earnings for the last quarter are -0 USD per share, whereas the estimation was -0 USD resulting in a -56.52% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Alterity Therapeutics revenue for the last year?▼
Alterity Therapeutics revenue for the last year amounts to 0 USD.
What is Alterity Therapeutics net income for the last year?▼
PRNAF net income for the last year is -15.7M USD.
How many employees does Alterity Therapeutics have?▼
As of April 02, 2026, the company has 10 employees.
In which sector is Alterity Therapeutics located?▼
Alterity Therapeutics operates in the Health Care sector.
When did Alterity Therapeutics complete a stock split?▼
The last stock split for Alterity Therapeutics was on January 09, 2023 with a ratio of 1:10.
Where is Alterity Therapeutics headquartered?▼
Alterity Therapeutics is headquartered in Melbourne, AU.